Abstract:Abstract Background: Aberrant splicing is a hallmark of cancer. For MYC-driven cancers, such as triple-negative breast cancer, hypersensitivity to spliceosome-targeted therapy is a novel anticancer strategy since it also triggers antitumorimmunity. Of the approximately 200 known spliceosomal genes, core spliceosomes are essential for cancer cell survival, yet the underlying mechanisms remain elusive. Methods: First, SNPRE representing the core spliceosomal Sm gene was screened using a multiomics database analysis approach. Then, we investigated the effect of SNRPE on the growth of TNBC cells in vitro and in vivo. We identified DDX20 from the interacting partners of SNPRE as a potential molecule involved in spliceosome vulnerability using coimmunoprecipitationtechniques. The mechanism of the SNRPE-DDX20 axis in tumor spliceosome therapeutic vulnerability was determined by various techniques,including RNA-seq, chromatin immunoprecipitation and other technologies. Results: In our research, SNRPE was upregulated in TNBC and predicted poor prognosis. Downregulation of SNRPE attenuated the vitality of TNBC in vivo and in vitro. We hypothesized and confirmed DDX20 as an important factor in core spliceosome therapeutic vulnerability. In DDX20-knockout TNBC cells, cell survival is no longer dependent onintracellular splicing activity orSNPRE expression. In DDX20/SNRPE double-downregulated cells, growth ability was restored due to MTOR reactivation via a splicing-independent pathway. In SNRPE-knockdown TNBC cells, ETV3 and its corepressor DDX20 function together to block MTOR expression to induce growth suppression. Once SNRPE expression was high, ETV3 bound to the C-terminus of DDX20 was replaced by SNRPE-containing components, whilethe binding affinity of released ETV3 to MTOR was reduced, and eventually, MTOR was expressed sufficiently to promote proliferation. Conclusions: Our results reveal that DDX20 is an adaptor in the crosstalk between RNA splicing (SnRNP components such as SNRPE) and the MTOR pathway in MYC-driven TNBC. Patients with high DDX20 expression are likely suitable for treatment with spliceosome modulators, leading to double killing effects by cell arrest and antitumorimmunity. Targeting DDX20 may serve as a therapeutic target for MYC-driven cancers.

MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression

Activation of ERβ Hijacks the Splicing Machinery to Trigger R-loop Formation in Triple-Negative Breast Cancer

A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple‐negative breast cancer

Upregulation of Serine Metabolism Enzyme PSAT1 Predicts Poor Prognosis and Promotes Proliferation, Metastasis and Drug Resistance of Clear Cell Renal Cell Carcinoma.

Oncogenic HJURP is driven by P53/ E2F1/FOXM1-axis regulated enhancer and potentiates TNBC proliferation and invasion

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple-Negative Breast Cancer

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

DDX20 interlinking with SNRPE endows MYC-driven triple-negative breast cancer therapeutic vulnerability in a splicing-independent manner

Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer

Circ_0084653 promotes the tumor progression and immune escape in triple-negative breast cancer via the deubiquitination of MYC and upregulation of SOX5

An in Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

SNRPB2 promotes triple‐negative breast cancer progression by controlling alternative splicing of MDM4 pre‐mRNA

Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis

USP1‐mediated deubiquitination of KDM1A promotes the malignant progression of triple‐negative breast cancer

RNA binding protein ZCCHC24 promotes tumorigenicity in triple-negative breast cancer

SPAG5 Upregulation Contributes to Enhanced C-Myc Transcriptional Activity Via Interaction with C-Myc Binding Protein in Triple-Negative Breast Cancer.

Ultrasound-responsive spherical nucleic acid against c-Myc/PD-L1 to enhance anti-tumoral macrophages in triple-negative breast cancer progression

Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of Dicer to accelerate triple-negative breast cancer progression

USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination

UCHL1 promotes cancer stemness in triple-negative breast cancer